Bestatin Treatment and the Peripheral Lymphocyte Population in Cancer Patients

  • H. Blomgren
  • L. E. Strender
  • F. Edsmyr
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 75)

Abstract

Bestatin, a substance produced by Streptomyces olivoreticuli, inhibits certain cell-membrane-associated enzymes and has been shown to augment immune responses in experimental animals. We have determined whether bestatin medication changed the peripheral lymphocyte population in 15 advanced cancer patients. After 2 weeks of daily, 30 mg oral bestatin medication, the lymphocyte counts remained essentially unchanged, but the frequency of E-rosette-forming lymphocytes increased. In vitro stimulation of the lymphocytes with PHA or PPD remained essentially unchanged while the natural-killer activity of the lymphocyte population increased in most patients. Bestatin treatment caused no detectable side effects.

Keywords

Placebo Toxicity Lymphoma Leukemia Creatinine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Aoyagi T, Suda H, Nagai M, Ogawa K, Suzuki J, Takeuchi T, Umezawa H (1976) Aminopeptidase activities on the surface of mammalian cells. Biochem Biophys Acta 452:131–143PubMedGoogle Scholar
  2. 2.
    Blomgren H (1975) Role of B-cells in the expression of the PPD response of human lymphocytes in vitro. Scand J Immunol 4:499–510PubMedCrossRefGoogle Scholar
  3. 3.
    Blomgren H, Glas U, Meén B, Wasserman J (1974) Blood lymphocytes after radiation therapy of mammary carcinoma. Acta Radiol Ther Phys Biol 13:185–200PubMedGoogle Scholar
  4. 4.
    Einhorn S, Blomgren H, Strander H (1978) Interferon and spontaneous cytotoxicity in man. I. Enhancement of spontaneous cytotoxicity of peripheral lymphocytes by human leukocyte interferon. Int J Cancer 22:405–412PubMedCrossRefGoogle Scholar
  5. 5.
    Jondal M, Holm G, Wigzell H (1972) Surface markers on human T and B lymphocytes. I. A large population of lymphocytes forming nonimmune rosettes with sheep red blood cells. J Exp Med 136:207–215PubMedCrossRefGoogle Scholar
  6. 6.
    Kasai M, Leclerc JC, McVay-Boudreau L, Shen FW, Cantor H (1979) Direct evidence that natural killer cells in nonimmune spleen cell populations prevent tumor growth in vivo. J Exp Med 149:1260–1264PubMedCrossRefGoogle Scholar
  7. 7.
    Kiessling R, Petrányi G, Klein G, Wigzell H (1975) Genetic variation of in vitro cytolytic activity and in vivo rejection potential of non-immunized semisyngeneic mice against a mouse lymphoma line. Int J Cancer 15:933PubMedCrossRefGoogle Scholar
  8. 8.
    Lilliehöök B, Blomgren H (1974) Strong stimulation of CBA lymphocytes in the mixed lymphocyte interaction with cells from the H-2 identical strain C3H. Scand J Immunol 3:627–635PubMedCrossRefGoogle Scholar
  9. 9.
    Suda H, Takita T, Aoyagi T, Umezawa H (1976) The structure of bestatin. J Antibiot (Tokyo) 29:100–101Google Scholar
  10. 10.
    Trinchieri G, Santoli D (1978) Antiviral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis. J Exp Med 147:1314–1333PubMedCrossRefGoogle Scholar
  11. 11.
    Umezawa H (1977) Recent advances in bioactive microbial secondary metabolites. J Antibiot (Tokyo) 30:138–163Google Scholar
  12. 12.
    Umezawa H, Aoyagi T, Suda H, Hamada M, Takeuchi T (1976) Bestatin, an inhibitor of aminopeptidase B produced by actinomycetes. J Antibiot (Tokyo) 29:97–99Google Scholar
  13. 13.
    Umezawa H, Ishizuka M, Aoyagi T, Takeuchi T (1976) Enhancement of delayed-type hypersensitivity by bestatin, an inhibitor of aminopeptidase B and leucine aminopeptidase. J Antibiot (Tokyo) 29:857–859Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1980

Authors and Affiliations

  • H. Blomgren
  • L. E. Strender
  • F. Edsmyr

There are no affiliations available

Personalised recommendations